Recordati Industria Chimica e Farmaceutica SPAAz. Post raggruppamento News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.11.24	RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% (GlobeNewswire)
04.10.24	RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE (GlobeNewswire)
23.03.21	RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE (GlobeNewswire)
22.02.21	RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%. (GlobeNewswire)
29.01.21	RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES (GlobeNewswire)
30.11.20	RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY (GlobeNewswire)
29.10.20	RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3% (GlobeNewswire)
01.10.20	RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED (GlobeNewswire)
21.09.20	RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION (GlobeNewswire)
30.07.20	RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8% (GlobeNewswire)
28.07.20	Recordati: Positive Ergebnisse der Phase-III-Studie LINC-3 mit Isturisa® (Osilodrostat) zur Behandlung des Cushing-Syndroms im Journal Lancet Diabetes & Endocrinology veröffentlicht (Businesswire)
28.07.20	Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing’s Disease Published in Lancet Diabetes & Endocrinology (Businesswire)
20.07.20	Isturisa® ist jetzt als medikamentöse Behandlung für das endogene Cushing-Syndrom in Deutschland erhältlich (Businesswire)
16.07.20	Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany (Businesswire)
17.06.20	Recordati Rare Diseases: Phase-III-Studie LINC-4 zu Isturisa® (Osilodrostat) erreicht primären Endpunkt bei Morbus Cushing (Businesswire)
17.06.20	Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing’s Disease (Businesswire)
17.06.20	RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE (GlobeNewswire)
02.06.20	Recordati Rare Diseases meldet europäischen Marktauftritt von Isturisa® (Osilodrostat) (Businesswire)
02.06.20	Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat) (Businesswire)
07.05.20	RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1% (GlobeNewswire)
29.04.20	RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018) (GlobeNewswire)
08.04.20	Recordati Rare Diseases now holds Isturisa® European MA (GlobeNewswire)
26.03.20	RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN (GlobeNewswire)
18.03.20	RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19 (GlobeNewswire)
18.03.20	BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%) (GlobeNewswire)
14.02.20	RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0% (GlobeNewswire)
15.01.20	RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED (GlobeNewswire)
15.11.19	RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT) (GlobeNewswire)
31.10.19	RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%). (GlobeNewswire)
23.10.19	RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED (GlobeNewswire)
30.07.19	RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1% (GlobeNewswire)
12.07.19	RECORDATI TO ACQUIRE WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) (GlobeNewswire)
24.06.19	RECORDATI RARE DISEASES, A WORLDWIDE LEADER IN RARE DISEASES AND ORPHAN DRUGS (GlobeNewswire)
08.05.19	RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2019. NEW THREE YEAR BUSINESS PLAN APPROVED (GlobeNewswire)
15.04.19	RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY (GlobeNewswire)
11.04.19	RECORDATI SHAREHOLDERS APPROVE THE 2018 ACCOUNTS. DIVIDEND € 0.92 PER SHARE (+8.2% vs 2017) (GlobeNewswire)
28.02.19	RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIV (GlobeNewswire)
11.02.19	RECORDATI: PRELIMINARY 2018 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +5.0%, EBITDA +9.8%, OPERATING INCOME +8.8%, NET INCOME +8.2% (GlobeNewswire)
06.02.19	RECORDATI OBTAINS EXCLUSIVE LICENSE FOR JUXTAPID® IN JAPAN (GlobeNewswire)
21.12.18	RECORDATI ACQUIRES TONIPHARM S.A.S. IN FRANCE (GlobeNewswire)
20.12.18	RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® (GlobeNewswire)
05.12.18	RECORDATI RECEIVES ORPHAN DRUG DESIGNATION FOR ITS INVESTIGATIONAL TREATMENT FOR NEUROTROPHIC KERATITIS (GlobeNewswire)
30.10.18	RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST NINE MONTHS 2018. REVENUES +5.1%, EBITDA +11.1%, OPERATING INCOME +9.6%, NET INCOME +8.2%. INTERIM DIVIDEND € 0.45 (+7.1%) (GlobeNewswire)
12.09.18	THE NINTH EDITION OF THE INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI HAS ANNOUNCED THE CALL FOR NOMINATIONS (GlobeNewswire)
26.07.18	RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST HALF 2018. REVENUES +6.9%, OPERATING INCOME +14.1%, NET INCOME +11.7% (GlobeNewswire)
11.06.18	RECORDATI ACQUIRES NATURAL POINT S.R.L. IN ITALY (GlobeNewswire)
08.05.18	RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST QUARTER 2018. REVENUES +7.2%, OPERATING INCOME +12.4%, NET INCOME +10.3% (GlobeNewswire)
09.04.18	RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN (GlobeNewswire)
15.03.18	RECORDATI: BOARD APPROVES THE 2017 ACCOUNTS. SALES € 1,288.1 MILLION (+11.6%), OPERATING INCOME € 406.5 MILLION (+24.1%) AND NET INCOME € 288.8 MILLION (+21.6%). 2017 DIVIDEND € 0.85 (+21.4%) (GlobeNewswire)
08.02.18	RECORDATI: PRELIMINARY 2017 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +11.6%, OPERATING INCOME +24.1%, NET INCOME +21.6% (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Recordati Industria Chimica e Farmaceutica SPAAz. Post raggruppamento

Aktien Top/Flop

Meistgelesene Nachrichten